BioNTech's updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine formulations that protect against ...

Health Canada approved Pfizer-BioNTech’s updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine ...

The NHS is offering autumn Covid boosters to the most vulnerable in October. Many pharmacies also now sell the Covid jab ...

Pfizer Canada says Health Canada has approved its updated COVID-19 vaccine that protects against one of the most recently ...

Novavax uses a protein-based vaccine strategy, which means people getting the vaccine receive a protein made by the virus ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...

Moderna's study looked at the vaccine in adults aged 50 and older, while Pfizer/BioNTech's trial focused on adults aged 18 to 64. Other rivals, meanwhile, include Sanofi/Novavax, which are ...

BioNTech and Regeneron are competing with rivals Moderna and MSD in the mRNA melanoma jab category, with the latter a little out in front with their mRNA-4157 (V940) candidate given in combination ...

Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option.

In this article, we are going to take a look at where Moderna Inc. (NASDAQ:MRNA) stands against Jim Cramer’s other must-watch stocks. In a recent episode of Mad Money, Jim Cramer traveled to ...

The pair aim to develop medicines involving mRNA, which is Moderna's specialty. Cardiometabolic indications like type 2 diabetes and obesity are the deal's focus. And it might -- but probably not ...